Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by AARON THRIFT and HASHEM EL-SERAG.
AARON THRIFT
Connection Strength
24.893
HASHEM EL-SERAG
  1. PNPLA3, Obesity, and Heavy Alcohol Use in Cirrhosis Patients May Exert a Synergistic Increase Hepatocellular Carcinoma Risk. Clin Gastroenterol Hepatol. 2024 Sep; 22(9):1858-1866.e4.
    View in: PubMed
    Score: 0.947
  2. An Electronic Health Record Model for Predicting Risk of Hepatic Fibrosis in Primary Care Patients. Dig Dis Sci. 2024 Jul; 69(7):2430-2436.
    View in: PubMed
    Score: 0.946
  3. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 2023 05; 20(5):338-349.
    View in: PubMed
    Score: 0.875
  4. Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score. PLoS One. 2023; 18(2):e0282309.
    View in: PubMed
    Score: 0.871
  5. Recent Decline in the Incidence of Hepatocellular Carcinoma in the United States. Clin Gastroenterol Hepatol. 2023 08; 21(9):2418-2420.e3.
    View in: PubMed
    Score: 0.838
  6. The Prevalence and Determinants of NAFLD and MAFLD and Their Severity in the VA Primary Care Setting. Clin Gastroenterol Hepatol. 2023 05; 21(5):1252-1260.e5.
    View in: PubMed
    Score: 0.833
  7. Associations of Duration, Intensity, and Quantity of Smoking With Risk of Gastric Intestinal Metaplasia. J Clin Gastroenterol. 2022 01 01; 56(1):e71-e76.
    View in: PubMed
    Score: 0.804
  8. Burden of Gastric Cancer. Clin Gastroenterol Hepatol. 2020 03; 18(3):534-542.
    View in: PubMed
    Score: 0.679
  9. Statin Use After Diagnosis of Hepatocellular Carcinoma Is Associated With Decreased Mortality. Clin Gastroenterol Hepatol. 2019 09; 17(10):2117-2125.e3.
    View in: PubMed
    Score: 0.654
  10. Ancestry and Risk of Hepatic Fibrosis and Inflammation in Patients With HCV Infection. Clin Gastroenterol Hepatol. 2019 08; 17(9):1912-1914.
    View in: PubMed
    Score: 0.644
  11. External Validation of the Michigan Barrett's Esophagus Prediction Tool. Clin Gastroenterol Hepatol. 2017 07; 15(7):1124-1126.
    View in: PubMed
    Score: 0.576
  12. Prediction Models for Gastrointestinal and Liver Diseases: Too Many Developed, Too Few Validated. Clin Gastroenterol Hepatol. 2016 12; 14(12):1678-1680.
    View in: PubMed
    Score: 0.555
  13. Sex and Racial Disparity in Incidence of Esophageal Adenocarcinoma: Observations and Explanations. Clin Gastroenterol Hepatol. 2016 Mar; 14(3):330-2.
    View in: PubMed
    Score: 0.524
  14. Metabolic syndrome and the risk of Barrett's oesophagus in white males. Aliment Pharmacol Ther. 2015 Jun; 41(11):1182-9.
    View in: PubMed
    Score: 0.502
  15. A multibiomarker risk score helps predict risk for Barrett's esophagus. Clin Gastroenterol Hepatol. 2014 Aug; 12(8):1267-71.
    View in: PubMed
    Score: 0.461
  16. No significant effects of smoking or alcohol consumption on risk of Barrett's esophagus. Dig Dis Sci. 2014 Jan; 59(1):108-16.
    View in: PubMed
    Score: 0.455
  17. Age at onset of GERD symptoms predicts risk of Barrett's esophagus. Am J Gastroenterol. 2013 Jun; 108(6):915-22.
    View in: PubMed
    Score: 0.439
  18. DNA Methylation Profile in Buffy Coat Identifies Methylation Differences Between Cirrhosis with and Without Hepatocellular Carcinoma. Cancers (Basel). 2025 Jan 15; 17(2).
    View in: PubMed
    Score: 0.248
  19. Serum levels of total bile acids are associated with an increased risk of HCC in patients with cirrhosis. Hepatol Commun. 2024 Nov 01; 8(11).
    View in: PubMed
    Score: 0.244
  20. Exposure to Light at Night and Risk of Cancer: A Systematic Review, Meta-Analysis, and Data Synthesis. Cancers (Basel). 2024 Jul 26; 16(15).
    View in: PubMed
    Score: 0.240
  21. Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis. Gut. 2024 Feb 16.
    View in: PubMed
    Score: 0.233
  22. Recent Trends in the Incidence of Gastric Cancer in the United States. J Clin Gastroenterol. 2024 01 01; 58(1):39-45.
    View in: PubMed
    Score: 0.231
  23. Race/ethnicity and sex differences in the association between area-level arsenic exposure concentration and hepatocellular carcinoma (HCC) incidence rates in Texas. An ecological study. Environ Res. 2024 Jan 01; 240(Pt 2):117538.
    View in: PubMed
    Score: 0.228
  24. Bioimpedance analysis predicts the etiology of cirrhosis in a prospective cohort study. Hepatol Commun. 2023 10 01; 7(10).
    View in: PubMed
    Score: 0.226
  25. Gastric Cancer Risk in Patients with Long-Term Use of Proton Pump Inhibitors: A Systematic Review and Meta-Analysis of Observational and Interventional Studies. Dig Dis Sci. 2023 09; 68(9):3732-3744.
    View in: PubMed
    Score: 0.223
  26. Association of Diet Quality with Metabolic (Dysfunction) Associated Fatty Liver Disease in Veterans in Primary Care. Nutrients. 2023 Jun 01; 15(11).
    View in: PubMed
    Score: 0.222
  27. Validation of a pre-endoscopy risk score for predicting the presence of gastric intestinal metaplasia in a U.S. population. Gastrointest Endosc. 2023 10; 98(4):569-576.e1.
    View in: PubMed
    Score: 0.221
  28. Risk Stratification Model for Hepatocellular Cancer in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2023 12; 21(13):3296-3304.e3.
    View in: PubMed
    Score: 0.220
  29. Prevention of Hepatocellular Carcinoma (HCC). White Paper of the Texas Collaborative Center for Hepatocellular Cancer (TeCH) Multi-stakeholder Conference. Clin Gastroenterol Hepatol. 2023 08; 21(9):2183-2192.
    View in: PubMed
    Score: 0.220
  30. Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology. 2023 03 01; 77(3):997-1005.
    View in: PubMed
    Score: 0.217
  31. Trends in Esophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma Incidence in the United States from 1992 to 2019. Cancers (Basel). 2022 Dec 08; 14(24).
    View in: PubMed
    Score: 0.215
  32. Using Natural Language Processing to Automatically Identify Dysplasia in Pathology Reports for Patients With Barrett's Esophagus. Clin Gastroenterol Hepatol. 2023 05; 21(5):1198-1204.
    View in: PubMed
    Score: 0.211
  33. Limits of the AGA Practice Update for Barrett's Esophagus Screening: A Proposal for Electronic Health Record-Adaptable Risk Models. Clin Gastroenterol Hepatol. 2023 Jul; 21(7):1963-1964.
    View in: PubMed
    Score: 0.211
  34. The Texas collaborative center for hepatocellular cancer: Reducing liver cancer mortality in Texas through coordination, collaboration and advocacy. Front Oncol. 2022; 12:953933.
    View in: PubMed
    Score: 0.210
  35. Development and Validation of the Houston-BEST, a Barrett's Esophagus Risk Prediction Model Adaptable to Electronic Health Records. Clin Gastroenterol Hepatol. 2023 08; 21(9):2424-2426.e0.
    View in: PubMed
    Score: 0.210
  36. Neighborhood-Level Factors Contribute to Disparities in Hepatocellular Carcinoma Incidence in Texas. Clin Gastroenterol Hepatol. 2023 05; 21(5):1314-1322.e5.
    View in: PubMed
    Score: 0.209
  37. Mediating Effects of Neighborhood-Level Socioeconomic Deprivation on the Association Between Race/Ethnicity and Advanced Hepatocellular Carcinoma. Cancer Epidemiol Biomarkers Prev. 2022 07 01; 31(7):1402-1409.
    View in: PubMed
    Score: 0.208
  38. Missed Opportunities for Screening or Surveillance Among Patients with Newly Diagnosed Non-cardia Gastric Adenocarcinoma. Dig Dis Sci. 2023 03; 68(3):761-769.
    View in: PubMed
    Score: 0.207
  39. Admixture Mapping in African Americans Identifies New Risk Loci for HCV-Related Cirrhosis. Clin Gastroenterol Hepatol. 2023 04; 21(4):1023-1030.e39.
    View in: PubMed
    Score: 0.207
  40. Response to Swami et al. Am J Gastroenterol. 2022 06 01; 117(6):1012.
    View in: PubMed
    Score: 0.207
  41. Inverse Association Between Gluteofemoral Obesity and Risk of Non-Cardia Gastric Intestinal Metaplasia. Clin Gastroenterol Hepatol. 2023 01; 21(1):64-71.
    View in: PubMed
    Score: 0.206
  42. Race/Ethnicity and Birthplace as Risk Factors for Gastric Intestinal Metaplasia in a Multiethnic United States Population. Am J Gastroenterol. 2022 02 01; 117(2):280-287.
    View in: PubMed
    Score: 0.202
  43. External validation of a model determining risk of neoplastic progression of Barrett's esophagus in a cohort of U.S. veterans. Gastrointest Endosc. 2022 06; 95(6):1113-1122.
    View in: PubMed
    Score: 0.201
  44. Risk Score Using Demographic and Clinical Risk Factors Predicts Gastric Intestinal Metaplasia Risk in a U.S. Population. Dig Dis Sci. 2022 09; 67(9):4500-4508.
    View in: PubMed
    Score: 0.199
  45. Alcohol consumption and the risk of gastric intestinal metaplasia in a U.S. Veterans population. PLoS One. 2021; 16(11):e0260019.
    View in: PubMed
    Score: 0.199
  46. Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare. Cancer Causes Control. 2021 Apr; 32(4):317-325.
    View in: PubMed
    Score: 0.188
  47. Persistent Challenges in the Hepatitis C Virus Care Continuum for Patients in a Central Texas Public Health System. Open Forum Infect Dis. 2020 Aug; 7(8):ofaa322.
    View in: PubMed
    Score: 0.182
  48. External Validation of Four Point-of-Care Noninvasive Scores for Predicting Advanced Hepatic Fibrosis in a Predominantly Hispanic NAFLD Population. Dig Dis Sci. 2021 07; 66(7):2387-2393.
    View in: PubMed
    Score: 0.182
  49. Prevalence of Barrett's esophagus and performance of societal?screening guidelines in an unreferred primary care population of U.S. veterans. Gastrointest Endosc. 2021 02; 93(2):409-419.e1.
    View in: PubMed
    Score: 0.181
  50. Increasing Incidence of Advanced Non-cardia Gastric Cancers Among Younger Hispanics in the USA. Dig Dis Sci. 2021 05; 66(5):1669-1672.
    View in: PubMed
    Score: 0.181
  51. Dietary Factors and Gastric Intestinal Metaplasia Risk Among US Veterans. Dig Dis Sci. 2021 05; 66(5):1600-1610.
    View in: PubMed
    Score: 0.181
  52. Low Yield of Hepatitis C Infection in an Outreach Screening Program in Harris County, Texas. Open Forum Infect Dis. 2020 Jul; 7(7):ofaa191.
    View in: PubMed
    Score: 0.180
  53. Systematic review with meta-analysis: prevalence of prior and concurrent Barrett's oesophagus in oesophageal adenocarcinoma patients. Aliment Pharmacol Ther. 2020 07; 52(1):20-36.
    View in: PubMed
    Score: 0.180
  54. Texas Has the Highest Hepatocellular Carcinoma Incidence Rates in the USA. Dig Dis Sci. 2021 03; 66(3):912-916.
    View in: PubMed
    Score: 0.179
  55. Prevalence of Gastric Intestinal Metaplasia in a Multiethnic US Veterans Population. Clin Gastroenterol Hepatol. 2021 02; 19(2):269-276.e3.
    View in: PubMed
    Score: 0.177
  56. Burden of Pancreatic Cancer: From Epidemiology to Practice. Clin Gastroenterol Hepatol. 2021 05; 19(5):876-884.
    View in: PubMed
    Score: 0.177
  57. Demographic and Lifestyle Risk Factors for Gastric Intestinal Metaplasia Among US Veterans. Am J Gastroenterol. 2020 03; 115(3):381-387.
    View in: PubMed
    Score: 0.177
  58. Use of Acid-Suppressant Medications After Diagnosis Increases Mortality in a Subset of Gastrointestinal Cancer Patients. Dig Dis Sci. 2020 09; 65(9):2691-2699.
    View in: PubMed
    Score: 0.174
  59. Sex and Race Disparities in the Incidence of Hepatocellular Carcinoma in the United States Examined through Age-Period-Cohort Analysis. Cancer Epidemiol Biomarkers Prev. 2020 01; 29(1):88-94.
    View in: PubMed
    Score: 0.173
  60. Prospective implementation of algorithmic patient selection for gastrostomy tube placement consultations: a pre- and post-intervention analysis. Clin Exp Gastroenterol. 2019; 12:231-237.
    View in: PubMed
    Score: 0.168
  61. Changing Trends in Colorectal Cancers (Detected by Screening, During Screening Intervals, or Associated With Nonadherence) Identify Possible Health Care System Quality Measures. Gastroenterology. 2019 02; 156(3):809-811.
    View in: PubMed
    Score: 0.161
  62. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology. 2018 12; 155(6):1828-1837.e2.
    View in: PubMed
    Score: 0.159
  63. Prior Diagnosis of Barrett's Esophagus Is Infrequent, but Associated with Improved Esophageal Adenocarcinoma Survival. Dig Dis Sci. 2018 11; 63(11):3112-3119.
    View in: PubMed
    Score: 0.159
  64. Underuse of Surgery Accounts for Racial Disparities in Esophageal Cancer Survival Times: A Matched Cohort Study. Clin Gastroenterol Hepatol. 2019 03; 17(4):657-665.e13.
    View in: PubMed
    Score: 0.158
  65. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans. Aliment Pharmacol Ther. 2018 08; 48(4):469-477.
    View in: PubMed
    Score: 0.158
  66. The Association Between Statin Use After Diagnosis and Mortality Risk in Patients With Esophageal Cancer: A Retrospective Cohort Study of United States Veterans. Am J Gastroenterol. 2018 09; 113(9):1310.
    View in: PubMed
    Score: 0.158
  67. Factors Associated With Recurrence of Barrett's Esophagus After Radiofrequency Ablation. Clin Gastroenterol Hepatol. 2019 01; 17(1):65-72.e5.
    View in: PubMed
    Score: 0.157
  68. Helicobacter pylori Infection Is Associated With Reduced Risk of Barrett's Esophagus: An Analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Am J Gastroenterol. 2018 08; 113(8):1148-1155.
    View in: PubMed
    Score: 0.157
  69. Incidence of gastric cancer in the USA during 1999 to 2013: a 50-state analysis. Int J Epidemiol. 2018 Jun 01; 47(3):966-975.
    View in: PubMed
    Score: 0.157
  70. Factors That Contribute to Indeterminate Results From the?QuantiFERON-TB Gold In-Tube Test in Patients With?Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2018 10; 16(10):1616-1621.e1.
    View in: PubMed
    Score: 0.151
  71. Obesity and Risk of Nonalcoholic Fatty Liver Disease: A Comparison of Bioelectrical Impedance Analysis and Conventionally-Derived Anthropometric Measures. Clin Gastroenterol Hepatol. 2017 12; 15(12):1965-1967.
    View in: PubMed
    Score: 0.147
  72. The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus. Am J Gastroenterol. 2017 Jul; 112(7):1049-1055.
    View in: PubMed
    Score: 0.144
  73. Clinical Manifestations of Helicobacter pylori-Negative Gastritis. Clin Gastroenterol Hepatol. 2017 Jul; 15(7):1037-1046.e3.
    View in: PubMed
    Score: 0.143
  74. Risk Profiles for Barrett's Esophagus Differ between New and Prevalent, and Long- and Short-Segment Cases. PLoS One. 2016; 11(12):e0169250.
    View in: PubMed
    Score: 0.142
  75. Shiftwork Is Not Associated with Increased Risk of NAFLD: Findings from the National Health and Nutrition Examination Survey. Dig Dis Sci. 2017 02; 62(2):526-533.
    View in: PubMed
    Score: 0.142
  76. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017 02; 14(2):122-132.
    View in: PubMed
    Score: 0.142
  77. Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. Gastroenterology. 2017 03; 152(4):812-820.e5.
    View in: PubMed
    Score: 0.141
  78. Acculturation and Nonalcoholic Fatty Liver Disease Risk Among Hispanics of Mexican Origin: Findings From the National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol. 2017 02; 15(2):310-312.
    View in: PubMed
    Score: 0.140
  79. Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus. Am J Gastroenterol. 2016 11; 111(11):1528-1535.
    View in: PubMed
    Score: 0.139
  80. Prevalence of Celiac Disease Among Unsuspected Patients Presenting to Open Access Endoscopy. Clin Gastroenterol Hepatol. 2017 01; 15(1):137-139.
    View in: PubMed
    Score: 0.139
  81. Inverse Association Between Gluteofemoral Obesity and Risk of?Barrett's Esophagus in a Pooled Analysis. Clin Gastroenterol Hepatol. 2016 10; 14(10):1412-1419.e3.
    View in: PubMed
    Score: 0.137
  82. Weight Change and Weight Cycling Are?Not?Associated With Risk of Barrett's?Esophagus. Clin Gastroenterol Hepatol. 2016 12; 14(12):1839-1840.
    View in: PubMed
    Score: 0.137
  83. Coffee or Tea, Hot or Cold, Are Not Associated With Risk of Barrett's Esophagus. Clin Gastroenterol Hepatol. 2016 May; 14(5):769-72.
    View in: PubMed
    Score: 0.132
  84. Premature Birth and Large for Gestational Age Are Associated with Risk of Barrett's Esophagus in Adults. Dig Dis Sci. 2016 Apr; 61(4):1139-47.
    View in: PubMed
    Score: 0.132
  85. Risk factors for Barrett's esophagus compared between African Americans and non-Hispanic Whites. Am J Gastroenterol. 2014 Dec; 109(12):1870-80.
    View in: PubMed
    Score: 0.123
  86. Fat mass by bioelectrical impedance analysis is not associated with increased risk of Barrett esophagus. J Clin Gastroenterol. 2014 Mar; 48(3):218-23.
    View in: PubMed
    Score: 0.117
  87. Temporal Changes in Risk Factors of Hepatocellular Carcinoma in a Prospective Cirrhosis Cohort. Clin Gastroenterol Hepatol. 2024 Dec 16.
    View in: PubMed
    Score: 0.062
  88. Neighborhood-level deprivation mediates racial and ethnic disparities in HCC diagnosis in Texas. Hepatol Commun. 2024 Nov 01; 8(11).
    View in: PubMed
    Score: 0.061
  89. Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol. 2024 Feb; 9(2):159-169.
    View in: PubMed
    Score: 0.058
  90. Synergistic Associations of PNPLA3 I148M Variant, Alcohol Intake, and Obesity With Risk of Cirrhosis, Hepatocellular Carcinoma, and Mortality. JAMA Netw Open. 2022 10 03; 5(10):e2234221.
    View in: PubMed
    Score: 0.053
  91. Perceptions of weight status and energy balance behaviors among patients with non-alcoholic fatty liver disease. Sci Rep. 2022 04 05; 12(1):5695.
    View in: PubMed
    Score: 0.051
  92. Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States. J Hepatol. 2022 02; 76(2):294-301.
    View in: PubMed
    Score: 0.049
  93. Correction to: Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2021 Aug; 66(8):2842.
    View in: PubMed
    Score: 0.049
  94. Prevalence and Predictors of Missed Dysplasia on Index Barrett's Esophagus Diagnosing Endoscopy in a Veteran Population. Clin Gastroenterol Hepatol. 2022 04; 20(4):e876-e889.
    View in: PubMed
    Score: 0.048
  95. Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes. Hepatology. 2020 10; 72(4):1242-1252.
    View in: PubMed
    Score: 0.046
  96. Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2021 07; 66(7):2439-2451.
    View in: PubMed
    Score: 0.046
  97. Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2021 01; 19(1):61-71.e15.
    View in: PubMed
    Score: 0.045
  98. Prevalence of Helicobacter pylori Positive Non-cardia Gastric Adenocarcinoma Is Low and Decreasing in a US Population. Dig Dis Sci. 2020 08; 65(8):2403-2411.
    View in: PubMed
    Score: 0.043
  99. Missed Opportunities for Screening and Surveillance of Barrett's Esophagus in Veterans with Esophageal Adenocarcinoma. Dig Dis Sci. 2019 02; 64(2):367-372.
    View in: PubMed
    Score: 0.040
  100. Long-term follow up of patients with obscure gastrointestinal bleeding examined with video capsule endoscopy. Medicine (Baltimore). 2018 Jul; 97(29):e11429.
    View in: PubMed
    Score: 0.039
  101. Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017 Aug; 15(8):1207-1217.e4.
    View in: PubMed
    Score: 0.036
  102. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J Hepatol. 2017 02; 66(2):355-362.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.